Introduction: Obesity is a preventable health condition, yet it remains a complex relapsing global health conundrum, triggering an array of comorbidities, including diabetes, dyslipidemia, hypertension, and mental hea...Introduction: Obesity is a preventable health condition, yet it remains a complex relapsing global health conundrum, triggering an array of comorbidities, including diabetes, dyslipidemia, hypertension, and mental health decline. This review intends to highlight the success of semaglutide for its therapeutic intervention for weight loss management in diabetics and non-diabetics and HbA1c reduction in type 2 diabetics. Methods: We searched and systematically reviewed the literature from within the past ten years on semaglutide utilization for weight loss and HbA1c reduction. Databases investigated included PMC, JAMA, Nature Medicine, and The Lancet, resulting in four original research articles that were systematically reviewed. Web consultations with WHO, CDC, and Healthy People 2030 were conducted to ascertain epidemiological obesity and diabetes data. AAFP and USPSTF references were included for obesity management and preventive care guidelines. Results: Based on results from systematically reviewing four original research studies, semaglutide can effectively reduce elevated weight and HbA1c, using the once-weekly subcutaneous injection formulation. A composite average percent weight loss of 8.27% (16 - 20 pounds) and an average HbA1c percent reduction rate of 1.07% (3 - 4 points) were attained. There were no major adverse events reported from any of the four original research studies related to the drug. Discussion: With evidence from several studies after its FDA approval, semaglutide delivers a promise for weight loss management and HbA1c reduction for appropriate patient populations. Clinician and patient education on its proper use should be continuously revisited.展开更多
Obesity is a chronic,relapsing,multifactorial pandemic defined as the excessive or abnormal accu・mulation of body fat due to genetic,biological,microbial,and environmental factors that promote a positive energy balanc...Obesity is a chronic,relapsing,multifactorial pandemic defined as the excessive or abnormal accu・mulation of body fat due to genetic,biological,microbial,and environmental factors that promote a positive energy balance mainly associated with increased intake and reduced consumption.1-3 Obesity is the consequence of enormous multisystem disorders,in eluding cardiovascular disease,4 type 2 diabetes,5 tumors,&sleep apnea,7-10 etc.,significantly increases mortality rate,11-13 and accounts for substantial elevation in health expenditures.14 Compared with Western countries.展开更多
文摘Introduction: Obesity is a preventable health condition, yet it remains a complex relapsing global health conundrum, triggering an array of comorbidities, including diabetes, dyslipidemia, hypertension, and mental health decline. This review intends to highlight the success of semaglutide for its therapeutic intervention for weight loss management in diabetics and non-diabetics and HbA1c reduction in type 2 diabetics. Methods: We searched and systematically reviewed the literature from within the past ten years on semaglutide utilization for weight loss and HbA1c reduction. Databases investigated included PMC, JAMA, Nature Medicine, and The Lancet, resulting in four original research articles that were systematically reviewed. Web consultations with WHO, CDC, and Healthy People 2030 were conducted to ascertain epidemiological obesity and diabetes data. AAFP and USPSTF references were included for obesity management and preventive care guidelines. Results: Based on results from systematically reviewing four original research studies, semaglutide can effectively reduce elevated weight and HbA1c, using the once-weekly subcutaneous injection formulation. A composite average percent weight loss of 8.27% (16 - 20 pounds) and an average HbA1c percent reduction rate of 1.07% (3 - 4 points) were attained. There were no major adverse events reported from any of the four original research studies related to the drug. Discussion: With evidence from several studies after its FDA approval, semaglutide delivers a promise for weight loss management and HbA1c reduction for appropriate patient populations. Clinician and patient education on its proper use should be continuously revisited.
文摘Obesity is a chronic,relapsing,multifactorial pandemic defined as the excessive or abnormal accu・mulation of body fat due to genetic,biological,microbial,and environmental factors that promote a positive energy balance mainly associated with increased intake and reduced consumption.1-3 Obesity is the consequence of enormous multisystem disorders,in eluding cardiovascular disease,4 type 2 diabetes,5 tumors,&sleep apnea,7-10 etc.,significantly increases mortality rate,11-13 and accounts for substantial elevation in health expenditures.14 Compared with Western countries.
